AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks

OBJECTIVE: The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatriptan for acute treatment of migraine in a double-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Headache
Autori principali: Tepper, Stewart J, Cady, Roger K, Silberstein, Stephen, Messina, John, Mahmoud, Ramy A, Djupesland, Per G, Shin, Paul, Siffert, Joao
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Ltd 2015
Soggetti:
Research Submissions
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4682470/
https://ncbi.nlm.nih.gov/pubmed/25941016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.12583
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi